The United Kingdom’s stock market has recently faced challenges, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns over global economic recovery. In such a climate, identifying undervalued stocks that may be trading below their fair value can offer potential opportunities for investors seeking to navigate these uncertain times.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Serabi Gold (AIM:SRB) |
£3.35 |
£6.32 |
47% |
|
Nichols (AIM:NICL) |
£9.72 |
£18.53 |
47.5% |
|
Motorpoint Group (LSE:MOTR) |
£1.38 |
£2.66 |
48.1% |
|
Informa (LSE:INF) |
£9.01 |
£17.24 |
47.7% |
|
Ibstock (LSE:IBST) |
£1.372 |
£2.50 |
45.1% |
|
Gym Group (LSE:GYM) |
£1.59 |
£2.99 |
46.9% |
|
Fevertree Drinks (AIM:FEVR) |
£8.30 |
£15.87 |
47.7% |
|
Barratt Redrow (LSE:BTRW) |
£3.815 |
£7.21 |
47.1% |
|
Anglo Asian Mining (AIM:AAZ) |
£2.70 |
£5.22 |
48.3% |
|
Advanced Medical Solutions Group (AIM:AMS) |
£2.21 |
£4.19 |
47.2% |
Let’s uncover some gems from our specialized screener.
Overview: Fevertree Drinks PLC, with a market cap of £959.32 million, develops and sells mixer drinks across the United Kingdom, the United States, Europe, and other international markets.
Operations: The company’s revenue is primarily generated from its non-alcoholic beverages segment, which accounts for £339.90 million.
Estimated Discount To Fair Value: 47.7%
Fevertree Drinks is trading at £8.3, significantly below its estimated fair value of £15.87, indicating it may be undervalued based on cash flows. Despite slower expected revenue growth of 10% annually compared to a 20% benchmark, it surpasses the UK market’s 4.3%. Earnings are anticipated to grow robustly at 20.8% per year, outpacing the UK market average of 13.6%. Recent board changes include Jeff Popkin’s retirement as Non-Executive Director after substantial contributions to international expansion efforts.
Overview: Convatec Group PLC develops, manufactures, and sells medical products, services, and technologies across Europe, North America, and internationally with a market cap of £4.80 billion.
Operations: The company’s revenue primarily comes from the development, manufacture, and sale of medical products and technologies, amounting to $2.36 billion.
Estimated Discount To Fair Value: 23.9%
Convatec Group is trading at £2.46, which is 23.9% below its estimated fair value of £3.23, highlighting potential undervaluation based on cash flows. Earnings are projected to grow at 16.1% annually, outpacing the UK market’s average growth of 13.6%. Despite high debt levels and slower revenue growth forecasts of 5.5%, recent executive changes with Jonny Mason as CEO and Fiona Ryder as CFO may drive strategic focus on simplification and productivity enhancements amidst Novo Holdings’ divestment plans.
